Abstract |
In a previous issue of the journal, Becker and colleagues present efficacy and safety data from a large study comparing febuxostat to allopurinol. The study showed non-inferiority of febuxostat 40 mg/day in lowering serum urate compared to allopurinol 200 to 300 mg/day. More importantly, the study showed a similar frequency of important cardiovascular adverse events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) for febuxostat 40 mg/day (0%), febuxostat 80 mg/day (0.4%) and allopurinol groups (0.4%). Other cardiac adverse event rates ( unstable angina, coronary revascularization, cerebral revascularization, transient ischemic attack, venous and peripheral arterial vascular thrombotic event, congestive heart failure, and arrhythmia) were also similar for febuxostat 40 mg/day (1.3%), febuxostat 80 mg/day (1.2%) and allopurinol groups (0.9%). A meta-analysis of safety data from published studies is presented.
|
Authors | Jasvinder A Singh |
Journal | Arthritis research & therapy
(Arthritis Res Ther)
Vol. 12
Issue 5
Pg. 136
( 2010)
ISSN: 1478-6362 [Electronic] England |
PMID | 20959031
(Publication Type: Comment, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Gout Suppressants
- Thiazoles
- Febuxostat
- Allopurinol
|
Topics |
- Allopurinol
(therapeutic use)
- Clinical Trials as Topic
- Febuxostat
- Gout
(drug therapy)
- Gout Suppressants
(therapeutic use)
- Humans
- Thiazoles
(therapeutic use)
|